Lv5
1320 积分 2024-02-26 加入
Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death
2个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
3个月前
已完结
Replication stress links structural and numerical cancer chromosomal instability
3个月前
已完结
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
3个月前
已完结
MultiOmics analysis of metabolic dysregulation and immune features in breast cancer
5个月前
已完结
Drug development of MET inhibitors: targeting oncogene addiction and expedience
5个月前
已完结
How does p53 work? Regulation by the intrinsically disordered domains
5个月前
已完结
c-Met: structure, functions and potential for therapeutic inhibition
6个月前
已完结
Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response
6个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
6个月前
已完结
皖公网安备34019202002308
